TrialCurveENRICH: reconstructed Kaplan–Meier curves
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Lancet. 2025 Oct 25;406(10514):1953–68. doi: 10.1016/S0140-6736(25)01432-1 |
|---|---|
| DOI | 10.1016/S0140-6736(25)01432-1 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival — Intention-to-treat population, all patients (ibrutinib–rituximab vs immunochemotherapy)
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Ibrutinib–rituximab 5.4 years; Immunochemotherapy 3.5 years. Survival at 2 years: Ibrutinib–rituximab 72%; Immunochemotherapy 69%. Hazard ratio Ibrutinib–rituximab vs Immunochemotherapy 0.70 (95% CI 0.53–0.92).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| Ibrutinib–rituximab | 199 | 93 | 5.4 |
| Immunochemotherapy | 198 | 121 | 3.5 |
- Ibrutinib–rituximab vs Immunochemotherapy: reconstructed HR 0.70 (95% CI 0.53–0.92)
Landmark survival (reconstructed)
| Time | Ibrutinib–rituximab | Immunochemotherapy |
|---|---|---|
| 1 yr | 80.3% | 81.1% |
| 2 yr | 71.6% | 68.7% |
| 3 yr | 64.4% | 54.5% |
| 5 yr | 51.1% | 39.5% |
| 7 yr | 47.7% | 30.1% |
Checks against the published figure
- hazard ratio: printed 0.69, reconstructed 0.698 pass
Progression-free survival — Pre-randomisation investigator choice of R-CHOP (ibrutinib–rituximab vs R-CHOP), intention-to-treat
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Ibrutinib–rituximab not reached; R-CHOP 2.2 years. Survival at 2 years: Ibrutinib–rituximab 72%; R-CHOP 61%. Hazard ratio Ibrutinib–rituximab vs R-CHOP 0.37 (95% CI 0.22–0.62).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| Ibrutinib–rituximab | 54 | 24 | not reached |
| R-CHOP | 53 | 44 | 2.2 |
- Ibrutinib–rituximab vs R-CHOP: reconstructed HR 0.37 (95% CI 0.22–0.62)
Landmark survival (reconstructed)
| Time | Ibrutinib–rituximab | R-CHOP |
|---|---|---|
| 1 yr | 79.6% | 74.9% |
| 2 yr | 72.2% | 61.1% |
| 3 yr | 70.3% | 35.5% |
| 5 yr | 52.1% | 19.7% |
| 7 yr | 52.1% | 8.5% |
Checks against the published figure
- hazard ratio: printed 0.37, reconstructed 0.372 pass
Progression-free survival — Pre-randomisation investigator choice of bendamustine–rituximab (ibrutinib–rituximab vs bendamustine–rituximab), intention-to-treat
From figure panel C · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Ibrutinib–rituximab 5.4 years; Bendamustine–rituximab 4.2 years. Survival at 2 years: Ibrutinib–rituximab 71%; Bendamustine–rituximab 72%. Hazard ratio Ibrutinib–rituximab vs Bendamustine–rituximab 0.89 (95% CI 0.64–1.23).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| Ibrutinib–rituximab | 145 | 69 | 5.4 |
| Bendamustine–rituximab | 145 | 77 | 4.2 |
- Ibrutinib–rituximab vs Bendamustine–rituximab: reconstructed HR 0.89 (95% CI 0.64–1.23)
Landmark survival (reconstructed)
| Time | Ibrutinib–rituximab | Bendamustine–rituximab |
|---|---|---|
| 1 yr | 80.6% | 83.3% |
| 2 yr | 71.4% | 72.1% |
| 3 yr | 62.1% | 62.1% |
| 5 yr | 50.9% | 47.4% |
| 7 yr | 44.6% | 38.1% |
Checks against the published figure
- hazard ratio: printed 0.91, reconstructed 0.89 pass
Overall survival — Intention-to-treat population, all patients (ibrutinib–rituximab vs immunochemotherapy)
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Ibrutinib–rituximab 7.2 years; Immunochemotherapy 5.7 years. Survival at 2 years: Ibrutinib–rituximab 81%; Immunochemotherapy 81%. Hazard ratio Ibrutinib–rituximab vs Immunochemotherapy 0.86 (95% CI 0.64–1.17).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| Ibrutinib–rituximab | 199 | 80 | 7.2 |
| Immunochemotherapy | 198 | 88 | 5.7 |
- Ibrutinib–rituximab vs Immunochemotherapy: reconstructed HR 0.86 (95% CI 0.64–1.17)
Landmark survival (reconstructed)
| Time | Ibrutinib–rituximab | Immunochemotherapy |
|---|---|---|
| 1 yr | 88.4% | 89.3% |
| 2 yr | 80.7% | 80.8% |
| 3 yr | 71.9% | 71.2% |
| 5 yr | 57.7% | 54.6% |
| 7 yr | 53.8% | 42.4% |
Checks against the published figure
- hazard ratio: printed 0.87, reconstructed 0.865 pass
Overall survival — Pre-randomisation investigator choice of R-CHOP (ibrutinib–rituximab vs R-CHOP), intention-to-treat
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Ibrutinib–rituximab not reached; R-CHOP 4.6 years. Survival at 2 years: Ibrutinib–rituximab 83%; R-CHOP 77%. Hazard ratio Ibrutinib–rituximab vs R-CHOP 0.63 (95% CI 0.36–1.10).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| Ibrutinib–rituximab | 54 | 21 | not reached |
| R-CHOP | 53 | 29 | 4.6 |
- Ibrutinib–rituximab vs R-CHOP: reconstructed HR 0.63 (95% CI 0.36–1.10)
Landmark survival (reconstructed)
| Time | Ibrutinib–rituximab | R-CHOP |
|---|---|---|
| 1 yr | 85.2% | 86.6% |
| 2 yr | 83.3% | 76.8% |
| 3 yr | 77.7% | 68.8% |
| 5 yr | 59.2% | 46.5% |
| 7 yr | 56.6% | 32.0% |
Checks against the published figure
- hazard ratio: printed 0.64, reconstructed 0.629 pass
Overall survival — Pre-randomisation investigator choice of bendamustine–rituximab (ibrutinib–rituximab vs bendamustine–rituximab), intention-to-treat
From figure panel C · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Ibrutinib–rituximab not reached; Bendamustine–rituximab 5.7 years. Survival at 2 years: Ibrutinib–rituximab 80%; Bendamustine–rituximab 82%. Hazard ratio Bendamustine–rituximab vs Ibrutinib–rituximab 1.02 (95% CI 0.71–1.47).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| Ibrutinib–rituximab | 145 | 58 | not reached |
| Bendamustine–rituximab | 145 | 59 | 5.7 |
- Bendamustine–rituximab vs Ibrutinib–rituximab: reconstructed HR 1.02 (95% CI 0.71–1.47)
Landmark survival (reconstructed)
| Time | Ibrutinib–rituximab | Bendamustine–rituximab |
|---|---|---|
| 1 yr | 89.6% | 90.2% |
| 2 yr | 79.7% | 82.3% |
| 3 yr | 69.7% | 72.8% |
| 5 yr | 57.4% | 58.0% |
| 7 yr | 52.2% | 48.3% |
Checks against the published figure
- hazard ratio: printed 1, reconstructed 0.979 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/enrich-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/enrich-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Lancet. 2025 Oct 25;406(10514):1953–68. doi: 10.1016/S0140-6736(25)01432-1 doi:10.1016/S0140-6736(25)01432-1. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/enrich
Report a problem with these data
Related trials
- Acalabrutinib vs chlorambucil + rituximab in CLL (Asian phase 3): BICR-assessed duration of response; BICR-assessed progression-free survival; Overall survi
- CLL12: Event-free survival (EFS); Overall survival (OS)
- ECHELON-2 (5-year update): Overall survival; Progression-free survival per investigator
- SUNMO (Japanese subgroup): Overall survival (interim analysis); Progression-free survival (centrally assessed, primar
- ADMYRE: Overall survival; Progression-free survival with PD confirmation by investigator's assessm
- AGILE (long-term follow-up): Overall survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials